Day: October 21, 2024

Angelini Pharma Enters Into An Exclusive Option Agreement With Cureverse to License Global Development and Commercialization Rights For A Novel and Innovative Clinical-Stage Brain Health Asset

The agreement gives Angelini Pharma an option to exclusive licensing rights to develop and commercialize CV-011, a clinical Phase 1 investigational novel compound with broad potential to treat brain health diseases Cureverse receives undisclosed upfront payments and is eligible for

Read More

(EDITORIAL from Korea Times on Oct. 21)

The National Intelligence Service (NIS) confirmed on Friday that North Korea has deployed troops to assist Russia in its war against Ukraine. At a National Security Council (NSC) meeting, the spy agency revealed aerial images showing hundreds of Nort…

Read More